A recent animal study has shown treated mice with 10058-F4 for 14 days was sufficient to delay tumor growth in a neuroblastoma transgenic mouse model and a xenograft mouse model, These data indicated that delaying tumor growth in vivo can be achieved by using a small molecule inhibitor that targets the c-Myc-Max interaction and targeting c-Myc-Max heterodimerization might be a good strategy for development of cancer therapy [20]. The gene discussed is MAX; the disease is cancer.